| Primary |
| Pneumonia |
18.6% |
| Febrile Neutropenia |
16.7% |
| Osteomyelitis |
8.8% |
| Sepsis |
7.0% |
| Urinary Tract Infection |
6.5% |
| Infection |
6.0% |
| Respiratory Tract Infection |
4.7% |
| Cholangitis |
3.3% |
| Pyrexia |
3.3% |
| Breast Cancer |
2.8% |
| Lung Infection |
2.8% |
| Pneumonia Aspiration |
2.8% |
| Respiratory Disorder |
2.8% |
| Lymphoma |
2.3% |
| Pleural Effusion |
2.3% |
| Cellulitis |
1.9% |
| Gastric Ulcer |
1.9% |
| Generalised Oedema |
1.9% |
| Pseudomonas Infection |
1.9% |
| Ventricular Tachycardia |
1.9% |
|
| Altered State Of Consciousness |
13.3% |
| Interstitial Lung Disease |
7.6% |
| Stevens-johnson Syndrome |
7.6% |
| Mental Disorder |
6.7% |
| Rash |
5.7% |
| Thrombocytopenia |
5.7% |
| Cardio-respiratory Arrest |
4.8% |
| Multi-organ Failure |
4.8% |
| Pseudomembranous Colitis |
4.8% |
| Anaphylactic Shock |
3.8% |
| Blood Pressure Decreased |
3.8% |
| Haematuria |
3.8% |
| Hypotension |
3.8% |
| Myoclonus |
3.8% |
| Sepsis |
3.8% |
| Shock |
3.8% |
| Tremor |
3.8% |
| Asthenia |
2.9% |
| Clostridium Difficile Colitis |
2.9% |
| Coordination Abnormal |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
12.9% |
| Drug Use For Unknown Indication |
12.6% |
| Sepsis |
9.6% |
| Pneumonia |
8.4% |
| Prophylaxis |
7.6% |
| Pyrexia |
7.1% |
| Infection Prophylaxis |
5.4% |
| Acute Lymphocytic Leukaemia |
3.8% |
| Multiple Myeloma |
3.7% |
| Infection |
3.0% |
| Antifungal Prophylaxis |
2.9% |
| Febrile Neutropenia |
2.9% |
| Insomnia |
2.9% |
| Stem Cell Transplant |
2.9% |
| Acute Myeloid Leukaemia Recurrent |
2.7% |
| Hypertension |
2.5% |
| Peripheral T-cell Lymphoma Unspecified |
2.5% |
| Glaucoma |
2.2% |
| Oropharyngeal Cancer Stage Unspecified |
2.2% |
| Premedication |
2.2% |
|
| Platelet Count Decreased |
9.9% |
| Pyrexia |
9.2% |
| White Blood Cell Count Decreased |
9.2% |
| Myoclonus |
6.9% |
| Interstitial Lung Disease |
6.1% |
| Renal Failure |
6.1% |
| Sepsis |
6.1% |
| Toxic Epidermal Necrolysis |
5.3% |
| Liver Disorder |
4.6% |
| Pancytopenia |
3.8% |
| Rash |
3.8% |
| Vomiting |
3.8% |
| White Blood Cell Count Increased |
3.8% |
| Anosmia |
3.1% |
| Depressed Level Of Consciousness |
3.1% |
| Myositis |
3.1% |
| Renal Failure Acute |
3.1% |
| Thrombocytopenia |
3.1% |
| Urine Output Decreased |
3.1% |
| Viral Rash |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.9% |
| Prophylaxis |
15.9% |
| Drug Use For Unknown Indication |
14.1% |
| Multiple Myeloma |
5.2% |
| Pneumonia |
4.4% |
| Acute Lymphocytic Leukaemia |
3.1% |
| Myelodysplastic Syndrome |
3.1% |
| Febrile Neutropenia |
3.0% |
| Infection Prophylaxis |
2.9% |
| Pyrexia |
2.8% |
| Acute Myeloid Leukaemia |
2.6% |
| Stem Cell Transplant |
2.3% |
| Hypertension |
2.2% |
| Allogenic Bone Marrow Transplantation Therapy |
2.0% |
| Immunosuppression |
1.9% |
| Constipation |
1.8% |
| Infection |
1.8% |
| Cancer Pain |
1.7% |
| Chronic Myeloid Leukaemia |
1.7% |
| Blood Bilirubin Increased |
1.6% |
|
| White Blood Cell Count Decreased |
17.7% |
| Sepsis |
10.1% |
| Pneumonia |
8.7% |
| Febrile Neutropenia |
5.8% |
| Pyrexia |
5.5% |
| Interstitial Lung Disease |
4.8% |
| Vomiting |
4.8% |
| Renal Failure Acute |
4.0% |
| Renal Impairment |
4.0% |
| Septic Shock |
4.0% |
| Death |
3.9% |
| Platelet Count Decreased |
3.5% |
| Renal Failure |
3.2% |
| Respiratory Failure |
3.2% |
| Thrombocytopenia |
3.2% |
| White Blood Cell Count Increased |
3.1% |
| Rhabdomyolysis |
2.7% |
| Stomatitis |
2.7% |
| Thrombotic Microangiopathy |
2.7% |
| Shock Haemorrhagic |
2.3% |
|
| Interacting |
| Product Used For Unknown Indication |
70.4% |
| Acute Promyelocytic Leukaemia |
25.9% |
| Infection |
3.7% |
|
| Drug Interaction |
66.7% |
| Myositis |
33.3% |
|
